Merrimack Pharmaceuticals Accounts Payable

Merrimack Pharmaceuticals (MACK) currently reports a accounts payable of $170K as of March 2024. That compares with $89K in the prior-year period — up 88.8% year over year. Use the charts on this page to explore Merrimack Pharmaceuticals's accounts payable history and peer comparisons.

Merrimack Pharmaceuticals's accounts payable increased from $89K to $170K — a 88.8% year-over-year increase (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Merrimack Pharmaceuticals reported $170K in accounts payable as of March 2024. That compares with $89K in the prior-year period — up 88.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $170K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Merrimack Pharmaceuticals, and consider following MACK for alerts when major investors trade the stock.

Merrimack Pharmaceuticals is classified in the Healthcare sector. On accounts payable, it currently shows $170K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MACK with unrelated industries.